酒精性肝病患者肠道微生态变化研究进展*

doi:10.3969/j.issn.1672-5069.2022.05.038

摘要/Abstract

摘要： 目的酒精性肝病(ALD)是全球肝脏疾病相关死亡的重要原因之一,已经成为全球范围内的卫生健康负担。越来越多的证据证明饮酒、肠道微生物失调和肝脏疾病之间存在密切的联系,肠道屏障破坏导致细菌及其产物的移位是关键的致病因素。近年来,通过对饮酒、肠道微生态与ALD进展之间相互作用的研究越来越多,寻找新的生物标志物和治疗靶点也成为预防和治疗ALD的热点。

关键词: 酒精性肝病, 肠道微生态, 作用机制, 标志物

Abstract: Objective Alcoholic liver disease (ALD) is one of the major causes of death related to liver disease over the world. The alcohol consumption and the related diseases have become a global health burden. There is growing evidence of strong correlation of intestinal microbiome disorders to liver diseases. The translocation of bacteria and their products caused by the destruction of the intestinal barrier is the key factor to lead to complications of liver diseases. In recent years, many new biomarkers and therapeutic targets are the hotspots in the field of ALD studies.

Key words: Alcoholic liver diseases, Intestinal microbiome, Pathogenesis, Markers

张改霞, 陈海震, 黄晶. 酒精性肝病患者肠道微生态变化研究进展^*[J]. 实用肝脏病杂志, 2022, 25(5): 757-760.

Zhang Gaixia, Chen Haizhen, Huang Jing. Intestinal microecology in patients with alcoholic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(5): 757-760.

参考文献

[1]Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers, 2018, 4(1): 16.
[2]Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut, 2016, 65(12): 2035-2044.
[3]Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol, 2019, 70(2): 260-272.
[4]Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol, 2012, 302(9): G966-978.
[5]Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology, 2011, 53(1): 96-105.
[6]Bull-Otterson L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One, 2013, 8(1): e53028.
[7]Bluemel S, Wang L, Kuelbs C, et al. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes, 2020, 11(3): 265-275.
[8]Lowe PP, Gyongyosi B, Satishchandran A, et al. Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice. PLoS One, 2017, 12(3): e0174544.
[9]Seo B, Jeon K, Moon S, et al. Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host Microbe, 2020, 27(1): 25-40,e26.
[10] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016, 65(5): 830-839.
[11] Engen PA, Green SJ, Voigt RM, et al. The gastrointestinal microbiome: Alcohol effects on the composition of intestinal microbiota. Alcohol Res, 2015, 37(2): 223-236.
[12] 栗红江, 何福亮, 陈来印. 酒精性肝病患者血清LP、LPO、NOS水平和肠道菌群分布变化分析. 实用肝脏病杂志, 2020, 23(4): 536-539.
[13] 延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究. 实用肝脏病杂志, 2019, 22(4): 518-521.
[14] Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology, 2014, 146(6): 1513-1524.
[15] Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology, 2015, 148(1): 203-214 e216.
[16] Bjorkhaug ST, Aanes H, Neupane SP, et al. Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut Microbes, 2019, 10(6): 663-675.
[17] Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67(6): 2150-2166.
[18] Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol, 2020, 72(3): 391-400.
[19] Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest, 2017, 127(7): 2829-2841.
[20] Jiang L, Lang S, Duan Y, et al. Intestinal virome in patients with alcoholic hepatitis. Hepatology, 2020, 72(6): 2182-2196.
[21] Zuo T, Lu XJ, Zhang Y, et al. Gut mucosal virome alterations in ulcerative colitis. Gut, 2019, 68(7): 1169-1179.
[22] Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 235-246.
[23] Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut, 2020, 69(12): 2232-2243.
[24] Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology, 2013, 58(1): 108-119.
[25] Rao RK. Acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Alcohol Clin Exp Res, 1998, 22(8): 1724-1730.
[26] Abdelmegeed MA, Banerjee A, Jang S, et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med, 2013, 65: 1238-1245.
[27] Chen P, Starkel P, Turner JR, et al. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology, 2015, 61(3): 883-894.
[28] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411.
[29] Bala S, Csak T, Saha B, et al. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol, 2016, 64(6): 1378-1387.
[30] Shao T, Zhao C, Li F, et al. Intestinal HIF-1alpha deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction. J Hepatol, 2018, 69(4): 886-895.
[31] Wang Y, Liu Y, Sidhu A, et al. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol, 2012, 303(1): G32-41.
[32] Li HS, Zhou YN, Li L, et al. HIF-1alpha protects against oxidative stress by directly targeting mitochondria. Redox Biol, 2019, 25: 101109.
[33] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575(7783): 505-511.
[34] Zhou R, Llorente C, Cao J, et al. Deficiency of intestinal alpha1-2-fucosylation exacerbates ethanol-induced liver disease in mice. Alcohol Clin Exp Res, 2020, 44(9): 1842-1851.
[35] Wang L, Fouts DE, Starkel P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe, 2016, 19(2): 227-239.
[36] Hendrikx T, Duan Y, Wang Y, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019, 68(8): 1504-1515.
[37] Wrzosek L, Ciocan D, Hugot C, et al. Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. Gut, 2021, 70(7): 1299-1308.
[38] Lang S, Duan Y, Liu J, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology, 2020, 71(2): 522-538.

酒精性肝病患者肠道微生态变化研究进展^*

Intestinal microecology in patients with alcoholic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	金盼盼, 张岭漪. PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展[J]. 实用肝脏病杂志, 2022, 25(4): 605-608.
[2]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[3]	冯宇, 杜振元, 李艳彬, 刘红. 酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析^*[J]. 实用肝脏病杂志, 2022, 25(1): 58-61.
[4]	刘丽霞, 林应源, 李华敏, 蔡水苗. 劳拉西泮与奥沙西泮治疗酒精性肝病并发酒精戒断综合征患者临床疗效对比研究[J]. 实用肝脏病杂志, 2021, 24(5): 709-712.
[5]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[6]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[7]	刘振, 潘光栋, 周峥, 刘强, 梁越, 黄科团, 郝树青, 杨建青. 肝细胞癌组织COPB2基因水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 115-118.
[8]	陈慧婷, 周永健. 肠道微生态影响肝脏疾病的若干进展与思考^*[J]. 实用肝脏病杂志, 2020, 23(6): 765-768.
[9]	王睿, 王绮夏, 马雄. 肠道微生态与自身免疫性肝病^*[J]. 实用肝脏病杂志, 2020, 23(6): 773-776.
[10]	栗红江, 何福亮, 陈来印. 酒精性肝病患者血清LP、LPO、NOS水平和肠道菌群分布变化分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 536-539.
[11]	黄橘村, 胡东辉, 张建军, 田德英. 慢病毒介导miR-203过表达对酒精性肝病大鼠肝损伤的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 171-174.
[12]	孙红菊, 王衍颜, 徐丛聪, 赵红. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 54-57.
[13]	徐玲, 任锋. 慢性肝病患者肝组织巨噬细胞功能变化研究新进展^*[J]. 实用肝脏病杂志, 2020, 23(1): 145-148.
[14]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[15]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.